However, the most recent ASCO guideline on GGT panels in patients with cancer proposes that when GGT is indicated for a patient with cancer, multigene panel testing should be offered if more than one gene is relevant, including BRCA1, BRCA2, PALB2, CDH1, PTEN, STK11, and TP53 genes (31). Here, BRCA2 is linked to cancer.